创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

崔晓腾, 方川, 刘博杨, 叶敏华, 曾亮, 万锋, 谢琦, 汪强虎, 汪秀星, 檀艳丽, 周秀萍, 吴旭东, 李学军, 郭洪波, 尤永平, 康春生. “十四五”胶质瘤基础与转化研究目标与共识[J]. 药学进展, 2021, 45(12): 927-932.
引用本文: 崔晓腾, 方川, 刘博杨, 叶敏华, 曾亮, 万锋, 谢琦, 汪强虎, 汪秀星, 檀艳丽, 周秀萍, 吴旭东, 李学军, 郭洪波, 尤永平, 康春生. “十四五”胶质瘤基础与转化研究目标与共识[J]. 药学进展, 2021, 45(12): 927-932.
CUI Xiaoteng, FANG Chuan, LIU Boyang, YE Minhua, ZENG Liang, WAN Feng, XIE Qi, WANG Qianghu, WANG Xiuxing, TAN Yanli, ZHOU Xiuping, WU Xudong, LI Xuejun, GUO Hongbo, YOU Yongping, KANG Chunsheng. Goals and Consensus of Basic and Translational Research on Glioma during China’s 14th Five-Year Plan (2021—2025)[J]. Progress in Pharmaceutical Sciences, 2021, 45(12): 927-932.
Citation: CUI Xiaoteng, FANG Chuan, LIU Boyang, YE Minhua, ZENG Liang, WAN Feng, XIE Qi, WANG Qianghu, WANG Xiuxing, TAN Yanli, ZHOU Xiuping, WU Xudong, LI Xuejun, GUO Hongbo, YOU Yongping, KANG Chunsheng. Goals and Consensus of Basic and Translational Research on Glioma during China’s 14th Five-Year Plan (2021—2025)[J]. Progress in Pharmaceutical Sciences, 2021, 45(12): 927-932.

“十四五”胶质瘤基础与转化研究目标与共识

Goals and Consensus of Basic and Translational Research on Glioma during China’s 14th Five-Year Plan (2021—2025)

  • 摘要: 国家“十四五”发展规划和2035年远景目标纲要提出,把保障人民健康放在优先发展的战略位置,全面推进健康中国建设。目前,我国神经系统肿瘤的发病人数和死亡人数均居世界首位,严重威胁我国人民身体健康。在此大背景下,中国医师协会脑胶质瘤专业委员会基础研究与转化学组整理总结目前胶质瘤研究进展,着眼于全新诊断治疗的策略突破、发病和耐药机制的深层次研究、全新胶质瘤动物模型的开发探索以及我国胶质瘤标准化资源共享平台的建立,旨在阐明中国胶质瘤研究方向,加速推动胶质瘤基础研究到临床应用的转化突破,实现科研成果从专利到临床转化的整体管线布局。

     

    Abstract: The “14th Five-Year Development Plan” (2021-2025) and the outline of long-term goals for 2035 in China put to priority the protection of people's health and construction of a “healthy China” in an all-round way.At present, the morbidity and mortality of nervous system tumors in China rank first in the world, which seriously threatens the health of the Chinese people.In this context, the basic and translational research group of Glioma Specialized Committee of the Chinese Medical Association reviewed and summarized the current research progress of glioma, focusing on the breakthroughs of new diagnostic and therapeutic strategies, the in-depth study of pathogenesis and drug resistance mechanisms, the development and exploration of new glioma animal models, and the establishment of glioma standardized resource sharing platform in China, so as to clarify the research direction of glioma in China, accelerate the translation from basic research to clinical application of glioma, and realize the overall pipeline layout of scientific research achievements from patent to clinical application.

     

/

返回文章
返回